Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 receptor agonist (GLP-1RA), has shown significant efficacy in weight loss and glycemic control in randomized controlled trials. Despite these promising results, there remains a critical need for real-world data to understand its effectiveness and tolerability across diverse patient populations. This is particularly relevant for obese or overweight midlife adults, a demographic often affected by Type 2 Diabetes (T2D) and its associated comorbidities, where real-world outcomes may differ from controlled trial settings.